20/20 Biolabs CEO granted 352,936 stock options

20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock.

Rhea-AI Filing Summary

20/20 Biolabs, Inc. reported that Chief Executive Officer Jonathan M. Cohen received a grant of stock options covering 352,936 shares of common stock. The options were granted at an exercise price of $0.0000 per share and are held directly.

According to the terms, these options vest in equal quarterly installments over four years, contingent on Cohen’s continued service with the company. After this grant, he holds stock options for 352,936 shares in total, aligning his compensation more closely with the company’s long-term performance.

Insider Trade Summary

Grant/Award: 352,936 shares

Grant/Award 1 txn

Insider Cohen Jonathan M

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	352,936	$0.00	$0.00

Holdings After Transaction: Stock Option — 352,936 contracts (Direct)

Footnotes (1)

1. F1. On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 20/20 Biolabs (AIDX) report for Jonathan M. Cohen?

20/20 Biolabs reported that CEO Jonathan M. Cohen received a stock option grant for 352,936 shares. These options were awarded at an exercise price of $0.0000 per share and represent a non-cash equity compensation award tied to his ongoing service.

How many shares are covered by the new stock option grant at 20/20 Biolabs (AIDX)?

The new stock option grant covers 352,936 shares of 20/20 Biolabs common stock. This entire amount is subject to a four-year vesting schedule, with shares vesting in equal quarterly installments as long as the CEO remains in continuous service.

What is the vesting schedule for Jonathan M. Cohen’s stock options at 20/20 Biolabs (AIDX)?

The stock options vest in equal quarterly installments over four years. Vesting is contingent on Jonathan M. Cohen’s continuous service to 20/20 Biolabs, meaning he must remain with the company for the full period to receive all optioned shares.

What is the exercise price of the new 20/20 Biolabs (AIDX) stock options?

The exercise price for the newly granted stock options is $0.0000 per share. This indicates the options were provided as a compensatory award rather than a market purchase, giving the CEO the right to acquire shares at no cash exercise cost.

How many stock option shares does Jonathan M. Cohen hold after this 20/20 Biolabs (AIDX) grant?

After the grant, Jonathan M. Cohen holds stock options covering a total of 352,936 shares. This total reflects the new award and ties his potential equity ownership to the company’s performance over the four-year vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:48 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Jonathan M

(Last) (First) (Middle)

C/O 20/20 BIOLABS, INC. 15810 GAITHER RD

SUITE 235

(Street)

GAITHERSBURG MD 20877

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$3.39	03/03/2026		A		352,936		(1)	03/03/2036	Common Stock	352,936	$0	352,936	D

Explanation of Responses:

1. On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer.

	/s/ Jonathan Cohen	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.